Revvity Inc.
RVTY
$124.13
+3.92%
Revvity, Inc. is a global life sciences and diagnostics company that provides reagents, instruments, and software for biopharma and academic research, as well as diagnostic tools for immunodiagnostics and newborn and reproductive health. Formed in 2023 from the rebranding of PerkinElmer, the company operates in two primary segments—Life Sciences and Diagnostics—and holds a strong competitive position as a diversified provider in the healthcare technology space. The current investor narrative centers on the company's post-rebranding transformation, with a focus on margin recovery, growth in its diagnostics portfolio, and the successful integration of its life sciences and diagnostics offerings. Recent stock momentum has been robust, with a 30.6% one-year gain, reflecting optimism about the company's strategic direction and operational execution.…
RVTY
Revvity Inc.
$124.13
Investment Opinion: Should I buy RVTY Today?
Based on the analysis, I rate RVTY as a Hold. The consensus recommendation is 'Buy' with an average target of $121.07, implying a modest 3.6% upside, which does not provide a compelling risk-reward. The stock has strong momentum and solid gross margins, but the high trailing PE and limited upside to targets suggest that much of the good news is already priced in.
Sign up to view all
RVTY 12-Month Price Forecast
The AI assessment is neutral, as the stock's valuation is stretched relative to its growth rate, but the company has solid fundamentals and positive analyst sentiment. The key factor is whether earnings growth can catch up to the valuation; if it does, the stock could rise, but if not, it may correct. I would upgrade to bullish if revenue growth accelerates above 10% or if the stock pulls back to a more attractive valuation. I would downgrade to bearish if operating margin falls below 10% or if revenue growth decelerates below 5%.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Revvity Inc.'s 12-month outlook, with a consensus price target around $121.07 and implied upside of -2.5% versus the current price.
Average Target
$121.07
0 analysts
Implied Upside
-2.5%
vs. current price
Analyst Count
—
covering this stock
Price Range
$100 - $145
Analyst target range
Revvity is covered by 15 analysts, with a consensus recommendation of 'Buy' and a mean rating of 2.29 (where 1 is Strong Buy and 5 is Sell). The average target price is $121.07, implying a modest upside of 3.6% from the current price of $116.84. The distribution of ratings is not provided, but the consensus leans bullish, with recent actions from firms like Evercore ISI (Outperform), TD Cowen (Buy), and Baird (Outperform) reinforcing positive sentiment. The target price range spans from $100.00 to $145.00, with the low target suggesting a potential downside of 14.4% and the high target implying a 24.1% upside. The wide spread indicates significant uncertainty about the company's future performance, likely due to the ongoing integration and transformation efforts. The high target assumes successful execution of growth strategies and margin expansion, while the low target reflects concerns about competitive pressures and potential revenue deceleration. Overall, the analyst community is cautiously optimistic, with a slight upward bias in price targets.
Bulls vs Bears: RVTY Investment Factors
Revvity presents a mixed picture: strong price momentum and solid gross margins are offset by a high trailing PE and modest revenue growth. The bull case rests on the company's ability to execute its transformation and expand margins, while the bear case highlights valuation risk and potential earnings disappointment. Currently, the evidence slightly favors the bulls given the positive analyst sentiment and strong technicals, but the narrow upside to targets and high multiple create a delicate balance. The key tension is whether the expected earnings growth (forward PE 19.8x) materializes; if it does, the stock can justify its premium, but any miss could trigger a sharp correction.
Bullish
- Strong momentum near 52-week high: RVTY is trading at $116.84, just 1.3% below its 52-week high of $118.34, with a 1-year gain of 30.6% versus the S&P 500's 20.4%. This reflects robust investor confidence and a clear uptrend, supported by a 24.3% gain over the past 3 months.
- Solid gross margin above 50%: Gross margin for Q1 2026 was 54.5%, up from 53.1% in Q4 2025, indicating strong pricing power and efficient cost management. This is well above the sector average and provides a cushion for operating leverage.
- Positive free cash flow generation: Free cash flow was $95.3 million in Q1 2026, with TTM FCF of $493.9 million, comfortably covering dividends (payout ratio 13.6%) and capital expenditures. This financial flexibility supports organic growth and potential M&A.
- Balanced revenue mix across segments: Life Sciences contributed $361.8 million and Diagnostics $349.3 million in Q1 2026, showing diversification that reduces segment-specific risk. This balance provides stability across different healthcare end-markets.
Bearish
- High trailing PE of 46.7x: The trailing PE is 46.7x, near the high end of its historical range (7.3x-114.9x), leaving little room for error. If earnings disappoint, the stock could face significant multiple compression.
- Modest revenue growth of 6.97%: Q1 2026 revenue grew only 6.97% YoY, which is low for a stock trading at a premium valuation. This growth rate may not justify the high multiple, especially if it decelerates further.
- Operating margin declined sequentially: Operating margin fell to 10.7% in Q1 2026 from 14.5% in Q4 2025, indicating potential cost pressures or investment phase. This could signal that margin expansion is not progressing as expected.
- Limited upside to analyst targets: The average analyst target of $121.07 offers only 3.6% upside, and the low target of $100 implies a 14.4% downside. This suggests that the stock may be fairly valued or slightly ahead of fundamentals.
RVTY Technical Analysis
Revvity's stock is in a clear uptrend, with a 1-year price change of +30.6% and a current price of $116.84, which sits at 98.6% of its 52-week range (low of $81.22, high of $118.34). This positioning near the highs indicates strong momentum and investor confidence, though it also suggests the stock may be approaching overbought conditions. The 6-month change of +21.7% and YTD change of +19.0% confirm the sustained upward trajectory, with the stock outperforming the S&P 500, which gained 20.4% over the same 1-year period.
Beta
1.07
1.07x market volatility
Max Drawdown
-30.1%
Largest decline past year
52-Week Range
$81-$124
Price range past year
Annual Return
+35.4%
Cumulative gain past year
| Period | RVTY Return | S&P 500 |
|---|---|---|
| 1m | +12.3% | +1.9% |
| 3m | +28.0% | +2.3% |
| 6m | +23.7% | +10.6% |
| 1y | +35.4% | +19.5% |
| ytd | +26.5% | +11.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
RVTY Fundamental Analysis
Revenue growth has been steady but modest, with the most recent quarter (Q1 2026) reporting revenue of $711.1 million, a 6.97% YoY increase. This growth is consistent with the prior quarters, which saw revenues of $772.1 million (Q4 2025), $698.9 million (Q3 2025), and $720.3 million (Q2 2025), indicating a stable, low-single-digit growth trajectory. The Life Sciences segment contributed $361.8 million and Diagnostics $349.3 million in the latest quarter, showing a balanced revenue mix. The company's profitability has improved, with net income of $40.7 million in Q1 2026, up from $42.2 million in Q1 2025, and a gross margin of 54.5% in Q1 2026, which is above the 53.1% gross margin reported in Q4 2025. Operating margin for Q1 2026 was 10.7%, down from 14.5% in Q4 2025, but the net margin of 5.7% is an improvement from the 6.4% in Q1 2025. The balance sheet remains solid, with a debt-to-equity ratio of 0.48, a current ratio of 1.68, and free cash flow of $95.3 million in Q1 2026, which is sufficient to cover capital expenditures and dividends. The company's ROE of 3.3% and ROA of 2.4% are modest, reflecting the capital-intensive nature of the business, but the consistent positive free cash flow generation supports financial stability.
Quarterly Revenue
$711118000.0B
2026-04
Revenue YoY Growth
+7.0%
YoY Comparison
Gross Margin
54.5%
Latest Quarter
Free Cash Flow
$493917000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is RVTY Overvalued?
Given that Revvity is profitable, the PE ratio is the primary valuation metric. The trailing PE is 46.7x, while the forward PE is 19.8x, indicating that the market expects significant earnings growth. This gap suggests that investors are pricing in a substantial improvement in profitability, likely driven by margin expansion and operational efficiencies. Compared to the industry average, Revvity's forward PE of 19.8x is at a premium to the sector's average of 15.2x, representing a 30% premium. This premium is justified by the company's strong gross margins of 53.1% and its leading position in the life sciences and diagnostics markets. Historically, the stock's PE has ranged from 7.3x to 114.9x over the past few years, with the current trailing PE of 46.7x near the higher end of that range. This suggests that the stock is trading at a premium to its historical average, reflecting optimism about future growth, but also leaving little room for error.
PE
46.7x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 7x~77x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
20.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks include a debt-to-equity ratio of 0.48, which is manageable but not negligible, and interest expenses of $24.7 million in Q1 2026 that could pressure earnings if rates rise. The company's net margin of 5.7% is thin, leaving limited buffer for cost overruns or revenue shortfalls. Additionally, the high trailing PE of 46.7x implies that the stock is priced for perfection; any earnings miss could lead to a de-rating. Free cash flow of $95.3 million in Q1 is positive, but it is only about 13% of revenue, indicating limited reinvestment capacity relative to the company's growth ambitions.